[
  {
    "ts": "2025-11-06T08:04:00+00:00",
    "headline": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
    "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
    "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
      "content": {
        "id": "5848522d-6379-3c44-88b1-55d6477f7e91",
        "contentType": "STORY",
        "title": "Novo Nordisk CFO outlines ‘ultimate defense’ against stock downgrades and lawsuits to retain weight-loss crown",
        "description": "",
        "summary": "\"The ultimate defence in our industry is in innovation,\" Knudsen told Fortune in an exclusive interview.",
        "pubDate": "2025-11-06T08:04:00Z",
        "displayTime": "2025-11-06T08:04:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4",
          "originalWidth": 2048,
          "originalHeight": 1365,
          "caption": "Karsten Munk Knudsen, chief financial officer of Novo Nordisk A/S",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/M_qy5Z_He6HZ19cMidPX0w--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 2048,
              "height": 1365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/JRApwcThX.P.KPvduaht_Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/2837a36aaa0002943060efa8c3d721d4.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-cfo-outlines-ultimate-080400832.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T10:47:09+00:00",
    "headline": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
    "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
    "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "b849e098-f319-3b50-b156-6496ffe1509d",
      "content": {
        "id": "b849e098-f319-3b50-b156-6496ffe1509d",
        "contentType": "STORY",
        "title": "Impressive Earnings May Not Tell The Whole Story For Eli Lilly (NYSE:LLY)",
        "description": "",
        "summary": "Unsurprisingly, Eli Lilly and Company's ( NYSE:LLY ) stock price was strong on the back of its healthy earnings report...",
        "pubDate": "2025-11-06T10:47:09Z",
        "displayTime": "2025-11-06T10:47:09Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/impressive-earnings-may-not-tell-104709866.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T12:58:55+00:00",
    "headline": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
    "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
    "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
    "source": "Investing.com",
    "provider": "yfinance",
    "raw": {
      "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
      "content": {
        "id": "da465711-34fe-3aef-ba8a-0193b69d9344",
        "contentType": "STORY",
        "title": "Stifel lifts Biogen to Buy, sees potential Alzheimer’s narrative shift",
        "description": "",
        "summary": "Investing.com -- Stifel upgraded Biogen (NASDAQ: BIIB) to Buy from Hold in a note Thursday, raising its price target to $202 from $144, saying the stock’s risk/reward profile is improving ahead of multiple clinical catalysts and a potential “narrative shift” in Alzheimer’s disease.",
        "pubDate": "2025-11-06T12:58:55Z",
        "displayTime": "2025-11-06T12:58:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Investing.com",
          "url": "https://www.investing.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/stifel-lifts-biogen-buy-sees-125855658.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T11:45:00+00:00",
    "headline": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
    "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
      "content": {
        "id": "57994221-aaeb-3d62-b328-698a7835bfe5",
        "contentType": "STORY",
        "title": "Lilly's selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive results from a Phase 2 trial evaluating the safety and efficacy of eloralintide, an investigational once-weekly, selective amylin receptor agonist, in 263 adults with obesity or overweight with at least one obesity-related comorbidity and without type 2 diabetes. At 48 weeks, all treatment arms of eloralintide met the primary endpoint, demonstrating superior mean weight reductions from 9.5% to 20.1% compared to 0.4% with placebo using th",
        "pubDate": "2025-11-06T11:45:00Z",
        "displayTime": "2025-11-06T11:45:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lillys-selective-amylin-agonist-eloralintide-114500341.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T15:23:00+00:00",
    "headline": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
    "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
    "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
      "content": {
        "id": "c84240ee-2762-3b00-8d10-c69c01b0f6f9",
        "contentType": "STORY",
        "title": "Chronic Heart Failure Market Analysis and Forecast, 2025-2035, Featuring AstraZeneca, Bristol Myers Squibb, Cytokinetics, Bayer, Eli Lilly and Other Leading Players",
        "description": "",
        "summary": "The market is expanding due to rising cardiovascular disease prevalence, an aging population, and advancements in treatments like SGLT2 inhibitors. Integration of digital health solutions and personalized medicine are key trends reshaping the landscape, enhancing patient outcomes and quality of life.Dublin, Nov. 06, 2025 (GLOBE NEWSWIRE) -- The \"Chronic Heart Failure Market - A Global and Regional Analysis: Analysis and Forecast, 2025-2035\" has been added to ResearchAndMarkets.com's offering. Co",
        "pubDate": "2025-11-06T15:23:00Z",
        "displayTime": "2025-11-06T15:23:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/chronic-heart-failure-market-analysis-152300107.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BAYN.DE"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "BMY"
            },
            {
              "symbol": "CYTK"
            },
            {
              "symbol": "JNJ"
            },
            {
              "symbol": "AMGN"
            },
            {
              "symbol": "4502.T"
            },
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "NOVN.SW"
            },
            {
              "symbol": "PFE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T16:06:47+00:00",
    "headline": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
    "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
    "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
    "source": "Financial Times",
    "provider": "yfinance",
    "raw": {
      "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
      "content": {
        "id": "4b9d559a-19b7-36d2-a7fb-f33e3d3c5310",
        "contentType": "STORY",
        "title": "Novo Nordisk again raises bid in battle for obesity start-up Metsera",
        "description": "",
        "summary": "Novo Nordisk has once again sweetened its offer for obesity biotech Metsera, as the Ozempic maker trades back-and-forth bids with Pfizer in a...",
        "pubDate": "2025-11-06T16:06:47Z",
        "displayTime": "2025-11-06T16:06:47Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "Financial Times",
          "url": "https://www.ft.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-nordisk-again-raises-bid-160647071.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:05:39+00:00",
    "headline": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
    "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies’ products will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
    "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
      "content": {
        "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
        "contentType": "STORY",
        "title": "Lilly, Novo to Lower Obesity Drug Prices in Deal With Trump",
        "description": "",
        "summary": "The deals with Lilly and Novo, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to certain people on Medicare, the government health plan for older Americans, according to senior administration officials.  The companies’ products will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, an official said, similar terms to those clinched by their rivals in previous drug-price deals.",
        "pubDate": "2025-11-06T17:05:39Z",
        "displayTime": "2025-11-06T17:05:39Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCZCsUJlU_eGSKICIOeYWw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WHyHD1H6zLz3nNV.CBM0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN.L"
            },
            {
              "symbol": "MRK.DE"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:13:17+00:00",
    "headline": "Eli Lilly, Novo to cut GLP-1 cost; airline stocks fall on FAA cut",
    "summary": "Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) and Novo Nordisk (NVO) will lower GLP-1 prices as a result of newly made agreements with the Trump administration. Airline stocks, including United (UAL), American (AAL), and Delta (DAL), are falling after the FAA announced a 10% decrease in flight traffic amid the government shutdown. Ralph Lauren (RL) stock is under pressure even after the company reported second quarter results that topped analyst estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
    "url": "https://finance.yahoo.com/video/eli-lilly-novo-cut-glp-181317651.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "d1f091d0-c956-38cc-ad12-4d44e9bfc9fd",
      "content": {
        "id": "d1f091d0-c956-38cc-ad12-4d44e9bfc9fd",
        "contentType": "VIDEO",
        "title": "Eli Lilly, Novo to cut GLP-1 cost; airline stocks fall on FAA cut",
        "description": "<p>Yahoo Finance's <a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/author/john-hyland/\">John Hyland</a> tracks Thursday's top moving stocks and biggest market stories in this<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-minute/\"> Market Minute</a>.</p>\n<p>Eli Lilly (<a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) and Novo Nordisk (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) will lower GLP-1 prices as a result of newly made agreements with the Trump administration.</p>\n<p>Airline stocks, including United (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/UAL\">UAL</a>), American (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/AAL\">AAL</a>), and Delta (<a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/quote/DAL\">DAL</a>), are falling after the FAA announced a 10% decrease in flight traffic amid the government shutdown.</p>\n<p>Ralph Lauren (<a data-i13n=\"cpos:8;pos:1\" href=\"https://finance.yahoo.com/quote/RL\">RL</a>) stock is under pressure even after the company reported second quarter results that topped analyst estimates.</p>\n<p>Stay up to date on the latest market action, minute-by-minute, with <a data-i13n=\"cpos:9;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-minute/\">Yahoo Finance's Market Minute.</a></p>",
        "summary": "Yahoo Finance's John Hyland tracks Thursday's top moving stocks and biggest market stories in this Market Minute. Eli Lilly (LLY) and Novo Nordisk (NVO) will lower GLP-1 prices as a result of newly made agreements with the Trump administration. Airline stocks, including United (UAL), American (AAL), and Delta (DAL), are falling after the FAA announced a 10% decrease in flight traffic amid the government shutdown. Ralph Lauren (RL) stock is under pressure even after the company reported second quarter results that topped analyst estimates. Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.",
        "pubDate": "2025-11-06T18:13:17Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/33fa5100-bb3c-11f0-be5d-2b22fef67da7",
          "originalWidth": 4668,
          "originalHeight": 2628,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/hyADVQPLqD7uDhFhnmq9BA--~B/aD0yNjI4O3c9NDY2ODthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/33fa5100-bb3c-11f0-be5d-2b22fef67da7.cf.webp",
              "width": 4668,
              "height": 2628,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/3YMN5GpGQek78hOg1xT6gA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/33fa5100-bb3c-11f0-be5d-2b22fef67da7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/eli-lilly-novo-cut-glp-181317651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/eli-lilly-novo-cut-glp-181317651.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "AAL"
            },
            {
              "symbol": "UAL"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "RL"
            },
            {
              "symbol": "DAL"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T19:19:58+00:00",
    "headline": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
    "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]",
    "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "e5ee382b-8e27-3302-8b8d-4b868de9bc5a",
      "content": {
        "id": "e5ee382b-8e27-3302-8b8d-4b868de9bc5a",
        "contentType": "STORY",
        "title": "Jim Cramer Recommends Eli Lilly Over Viking Therapeutics",
        "description": "",
        "summary": "Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of the stocks Jim Cramer was asked about. Mentioning that they are a long-term shareholder of VKTX, a caller said that they have been observing the bidding war between Novo Nordisk and Pfizer for Metsera. Cramer commented: “Yeah, I know, and I’ve watched that, and I don’t, I think […]",
        "pubDate": "2025-11-06T19:19:58Z",
        "displayTime": "2025-11-06T19:19:58Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6",
          "originalWidth": 1000,
          "originalHeight": 666,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/E2lv2kKRF2jXt8F.V84xVw--~B/aD02NjY7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 1000,
              "height": 666,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/BN9PfJYu5RffW4DiInJR2Q--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/7b1d6a1350c79cef49b9cb2889204dd6.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/jim-cramer-recommends-eli-lilly-191958282.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "VKTX"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T19:02:50+00:00",
    "headline": "Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo",
    "summary": "The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their weight-loss drugs.",
    "url": "https://www.investors.com/news/technology/weight-loss-drugs-trump-administration-mfn-eli-lilly-novo-nordisk/?src=A00220&yptr=yahoo",
    "source": "Investor's Business Daily",
    "provider": "yfinance",
    "raw": {
      "id": "661a1027-3388-3058-b15a-761440b83fd2",
      "content": {
        "id": "661a1027-3388-3058-b15a-761440b83fd2",
        "contentType": "STORY",
        "title": "Trump Slashes Weight-Loss Drug Prices By Up To 74% In Deal With Lilly, Novo",
        "description": "",
        "summary": "The Trump administration announced deals Thursday with Eli Lilly and Novo Nordisk to slash the prices of their weight-loss drugs.",
        "pubDate": "2025-11-06T19:02:50Z",
        "displayTime": "2025-11-06T19:02:50Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/661a1027-3388-3058-b15a-761440b83fd2/trump-slashes-weight-loss.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/ibd.com/b61eb215ccb53624274765e4beee9de9",
          "originalWidth": 1012,
          "originalHeight": 572,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OrKmD8IabYkfGxu4UJyFug--~B/aD01NzI7dz0xMDEyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/ibd.com/b61eb215ccb53624274765e4beee9de9.cf.webp",
              "width": 1012,
              "height": 572,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g66IbdJvyh.X..xb0y_C2A--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/ibd.com/b61eb215ccb53624274765e4beee9de9.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Investor's Business Daily",
          "url": "http://www.investors.com/"
        },
        "canonicalUrl": {
          "url": "https://www.investors.com/news/technology/weight-loss-drugs-trump-administration-mfn-eli-lilly-novo-nordisk/?src=A00220&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:54:00+00:00",
    "headline": "Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improv",
    "url": "https://finance.yahoo.com/news/lilly-u-government-agree-expand-185400769.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "e0bfe53f-a846-3432-a201-cbf73f9158ee",
      "content": {
        "id": "e0bfe53f-a846-3432-a201-cbf73f9158ee",
        "contentType": "STORY",
        "title": "Lilly and U.S. government agree to expand access to obesity medicines to millions of Americans",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced an agreement with the U.S. government to expand access to its obesity medicines and reduce patient costs. The agreement builds on Lilly's longstanding commitment to finding solutions with policymakers that improve access to life-changing medicines. In 2020, Lilly partnered with the Trump Administration on a pilot program that paved the way for Lilly to be the first company to cap out-of-pocket insulin costs at $35 per month. Lilly will now improv",
        "pubDate": "2025-11-06T18:54:00Z",
        "displayTime": "2025-11-06T18:54:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-u-government-agree-expand-185400769.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-u-government-agree-expand-185400769.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:35:19+00:00",
    "headline": "Update: Eli Lilly, Novo Nordisk to Cut Obesity Drug Prices Under Deals With Trump Administration",
    "summary": "(Updates with additional details in the third to fifth paragraphs.) Eli Lilly (LLY) and Novo Nord",
    "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-183519292.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "e9b9c84b-f35b-31ca-8e1d-8285a8e2a890",
      "content": {
        "id": "e9b9c84b-f35b-31ca-8e1d-8285a8e2a890",
        "contentType": "STORY",
        "title": "Update: Eli Lilly, Novo Nordisk to Cut Obesity Drug Prices Under Deals With Trump Administration",
        "description": "",
        "summary": "(Updates with additional details in the third to fifth paragraphs.) Eli Lilly (LLY) and Novo Nord",
        "pubDate": "2025-11-06T18:35:19Z",
        "displayTime": "2025-11-06T18:35:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-183519292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-183519292.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:34:00+00:00",
    "headline": "Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market",
    "summary": "The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.",
    "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-weight-loss-drugs-medicare-trump-a0b02e56?siteid=yhoof2&yptr=yahoo",
    "source": "Barrons.com",
    "provider": "yfinance",
    "raw": {
      "id": "800f8cc9-50dd-36cc-ad8b-9fd66b1d008c",
      "content": {
        "id": "800f8cc9-50dd-36cc-ad8b-9fd66b1d008c",
        "contentType": "STORY",
        "title": "Novo Nordisk and Eli Lilly Can Sell Their Weight-Loss Drugs to Medicare Market",
        "description": "",
        "summary": "The agreement, announced by the White House, potentially unlocks a major new market for the mega-blockbuster drugs.",
        "pubDate": "2025-11-06T18:34:00Z",
        "displayTime": "2025-11-06T18:34:00Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/800f8cc9-50dd-36cc-ad8b-9fd66b1d008c/novo-nordisk-and-eli-lilly.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e",
          "originalWidth": 320,
          "originalHeight": 65,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dzJ1YBP0KGeG_11a2M96gg--~B/aD02NTt3PTMyMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 320,
              "height": 65,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Yw_3eAv_WYSK2a6PV_FD9g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/Barrons.com/12ea0f43d8f8307249a68d1cb2e0587e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Barrons.com",
          "url": "http://www.barrons.com/"
        },
        "canonicalUrl": {
          "url": "https://www.barrons.com/articles/novo-nordisk-eli-lilly-weight-loss-drugs-medicare-trump-a0b02e56?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "AZN"
            },
            {
              "symbol": "AZNCF"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:16:57+00:00",
    "headline": "Is Eli Lilly’s Recent FDA Progress Making the Stock a Bargain in 2025?",
    "summary": "Ever wondered if Eli Lilly's stock is offering genuine value, or if the price is running ahead of itself? Let’s dig into what’s happening beneath those eye-catching numbers. Shares have climbed an impressive 13.8% in just the last week, and are up 20.2% over the past year, showing that investors remain bullish, while possibly adjusting their risk and reward expectations. Recent headlines have amplified optimism about Eli Lilly’s drug pipeline, including FDA progress for obesity and diabetes...",
    "url": "https://finance.yahoo.com/news/eli-lilly-recent-fda-progress-181657273.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "96e70173-022d-385b-aada-6a3c77565a01",
      "content": {
        "id": "96e70173-022d-385b-aada-6a3c77565a01",
        "contentType": "STORY",
        "title": "Is Eli Lilly’s Recent FDA Progress Making the Stock a Bargain in 2025?",
        "description": "",
        "summary": "Ever wondered if Eli Lilly's stock is offering genuine value, or if the price is running ahead of itself? Let’s dig into what’s happening beneath those eye-catching numbers. Shares have climbed an impressive 13.8% in just the last week, and are up 20.2% over the past year, showing that investors remain bullish, while possibly adjusting their risk and reward expectations. Recent headlines have amplified optimism about Eli Lilly’s drug pipeline, including FDA progress for obesity and diabetes...",
        "pubDate": "2025-11-06T18:16:57Z",
        "displayTime": "2025-11-06T18:16:57Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/uZWvuDuy6_Wr6cKvxAFZcw--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g78F5NO5pySOmBHzFi6.eA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/5eef176f2a2dc130a63fafe4bd1968dd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-recent-fda-progress-181657273.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-recent-fda-progress-181657273.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:51:43+00:00",
    "headline": "Lilly, Novo Cut Deal to Lower Drug Prices in Exchange for Tariff Relief",
    "summary": "Eli Lilly & Co.&nbsp;and&nbsp;Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients.&nbsp;President Donald Trump spoke about it in the Oval Office.",
    "url": "https://finance.yahoo.com/video/lilly-novo-cut-deal-lower-175143453.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "417dd9e5-76ff-390f-ba05-c1267278daba",
      "content": {
        "id": "417dd9e5-76ff-390f-ba05-c1267278daba",
        "contentType": "VIDEO",
        "title": "Lilly, Novo Cut Deal to Lower Drug Prices in Exchange for Tariff Relief",
        "description": "Eli Lilly & Co. and Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients. President Donald Trump spoke about it in the Oval Office.",
        "summary": "Eli Lilly & Co.&nbsp;and&nbsp;Novo Nordisk A/S cut a deal with the Trump administration to lower prices on their blockbuster weight-loss drugs in exchange for tariff relief and wider access for Medicare patients.&nbsp;President Donald Trump spoke about it in the Oval Office.",
        "pubDate": "2025-11-06T17:51:43Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_markets_video_2/a33b58933f75707851025d4fee695738",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Pg8wxMkK_Yf6kjssfT2neg--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/bloomberg_markets_video_2/a33b58933f75707851025d4fee695738.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/tkSVggQfe5kGcAXDFzXrjA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_markets_video_2/a33b58933f75707851025d4fee695738.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/lilly-novo-cut-deal-lower-175143453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/lilly-novo-cut-deal-lower-175143453.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:50:41+00:00",
    "headline": "Ozempic, weight loss drug prices to drop in Medicare deal with Trump",
    "summary": "Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli Lilly and Novo Nordisk",
    "url": "https://qz.com/novo-lilly-deal-trump-low-price-glp-1-weight-loss-ozempic",
    "source": "Quartz",
    "provider": "yfinance",
    "raw": {
      "id": "eb90e785-2bd0-39a7-8b98-392828377710",
      "content": {
        "id": "eb90e785-2bd0-39a7-8b98-392828377710",
        "contentType": "STORY",
        "title": "Ozempic, weight loss drug prices to drop in Medicare deal with Trump",
        "description": "",
        "summary": "Popular GLP-1 drugs like Ozempic will get cheaper in exchange for partial Medicare coverage, opening up new markets for Eli Lilly and Novo Nordisk",
        "pubDate": "2025-11-06T17:50:41Z",
        "displayTime": "2025-11-06T17:50:41Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/quartz_855/1212e095ca31eb91a6c71d4dddd592e7",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/fD0Rwf42RtZxrobsUhu_hA--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/quartz_855/1212e095ca31eb91a6c71d4dddd592e7.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Ie7jEofJRslUfYR6GFyaFQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/quartz_855/1212e095ca31eb91a6c71d4dddd592e7.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Quartz",
          "url": "https://qz.com/"
        },
        "canonicalUrl": {
          "url": "https://qz.com/novo-lilly-deal-trump-low-price-glp-1-weight-loss-ozempic",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trump-inks-deals-cut-prices-175041145.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T17:07:05+00:00",
    "headline": "Eli Lilly, Novo Nordisk Cut Weight-Loss Drug Prices in Deals With Trump Administration",
    "summary": "Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, which is expanding coverage of the drugs in the Medicare and Medicaid health-insurance programs.  The companies will sell their GLP-1-containing drugs, including Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro and Zepbound, to the Medicare and Medicaid programs for $245 a month, to treat both diabetes and obesity, according to senior administration officials.",
    "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/eli-lilly-novo-nordisk-cut-weight-loss-drug-prices-in-deal-with-trump-administration-T6sL0JKbt8aIJZSFUQeC?siteid=yhoof2&yptr=yahoo",
    "source": "The Wall Street Journal",
    "provider": "yfinance",
    "raw": {
      "id": "cfd2ce23-5b76-31f3-b86a-ef6e28687a3b",
      "content": {
        "id": "cfd2ce23-5b76-31f3-b86a-ef6e28687a3b",
        "contentType": "STORY",
        "title": "Eli Lilly, Novo Nordisk Cut Weight-Loss Drug Prices in Deals With Trump Administration",
        "description": "",
        "summary": "Eli Lilly and Novo Nordisk are cutting prices for popular weight-loss drugs in deals struck with the Trump administration, which is expanding coverage of the drugs in the Medicare and Medicaid health-insurance programs.  The companies will sell their GLP-1-containing drugs, including Novo Nordisk’s Ozempic and Wegovy, and Eli Lilly’s Mounjaro and Zepbound, to the Medicare and Medicaid programs for $245 a month, to treat both diabetes and obesity, according to senior administration officials.",
        "pubDate": "2025-11-06T17:07:05Z",
        "displayTime": "2025-11-06T17:07:05Z",
        "isHosted": false,
        "bypassModal": false,
        "previewUrl": "https://finance.yahoo.com/m/cfd2ce23-5b76-31f3-b86a-ef6e28687a3b/eli-lilly-novo-nordisk-cut.html",
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/wsj.com/f4767431cd75833f30c96c5495b7215e",
          "originalWidth": 1280,
          "originalHeight": 640,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/dlZbu0KnvFPGigiynyHZog--~B/aD02NDA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/wsj.com/f4767431cd75833f30c96c5495b7215e.cf.webp",
              "width": 1280,
              "height": 640,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/lkDgIusmDAv3i89SnLjeVw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/wsj.com/f4767431cd75833f30c96c5495b7215e.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "The Wall Street Journal",
          "url": "http://www.wsj.com/"
        },
        "canonicalUrl": {
          "url": "https://www.wsj.com/livecoverage/stock-market-today-dow-sp-500-nasdaq-11-06-2025/card/eli-lilly-novo-nordisk-cut-weight-loss-drug-prices-in-deal-with-trump-administration-T6sL0JKbt8aIJZSFUQeC?siteid=yhoof2&yptr=yahoo",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": null,
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T14:32:00+00:00",
    "headline": "Novo, Lilly cut deal with Trump to lower prices of obesity drugs",
    "summary": "The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.",
    "url": "https://www.biopharmadive.com/news/lilly-novo-trump-obesity-drug-pricing-deal-zepbound-wegovy/804905/",
    "source": "BioPharma Dive",
    "provider": "yfinance",
    "raw": {
      "id": "686687e8-13fb-30d4-af51-5ff93cb27fc0",
      "content": {
        "id": "686687e8-13fb-30d4-af51-5ff93cb27fc0",
        "contentType": "STORY",
        "title": "Novo, Lilly cut deal with Trump to lower prices of obesity drugs",
        "description": "",
        "summary": "The agreement will make Wegovy and Zepbound available to some Medicare enrollees for $245 per month, and starter doses of pill versions, once approved, for $149 monthly.",
        "pubDate": "2025-11-06T14:32:00Z",
        "displayTime": "2025-11-06T14:32:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1",
          "originalWidth": 1600,
          "originalHeight": 900,
          "caption": "David Ricks, CEO of Eli Lilly, speaks alongside U.S. President Donald Trump, administration officials and fellow pharmaceutical executives on November 06, 2025 in Washington, DC.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1u9Re32Z.69y9d3.q5kNYQ--~B/aD05MDA7dz0xNjAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 1600,
              "height": 900,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/8RvWVyCDOXOFlLS56Rdufw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/biopharma_dive_768/8ff02a124e40e32c10243f75d8c8a2e1.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "BioPharma Dive",
          "url": "https://biopharmadive.com/"
        },
        "canonicalUrl": {
          "url": "https://www.biopharmadive.com/news/lilly-novo-trump-obesity-drug-pricing-deal-zepbound-wegovy/804905/",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/novo-lilly-cut-deal-trump-143200679.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NOVO-B.CO"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T21:08:31+00:00",
    "headline": "Lilly, Novo to Lower Obesity Drug Prices in Trump Deal",
    "summary": "The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.  The companies’ medicines will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, a senior administration official said, similar terms to those clinched by their rivals in previous drug-price deals.",
    "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
    "source": "Bloomberg",
    "provider": "yfinance",
    "raw": {
      "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
      "content": {
        "id": "98cbc297-7e95-3688-8125-f7955e8a77c7",
        "contentType": "STORY",
        "title": "Lilly, Novo to Lower Obesity Drug Prices in Trump Deal",
        "description": "",
        "summary": "The deals, announced Thursday at a White House event with President Donald Trump, will make some of the most popular drugs in the world available to more people on Medicare, the government health plan for older Americans.  The companies’ medicines will receive a three-year grace period from Trump’s forthcoming duties on pharmaceutical imports, a senior administration official said, similar terms to those clinched by their rivals in previous drug-price deals.",
        "pubDate": "2025-11-06T21:08:31Z",
        "displayTime": "2025-11-06T21:08:31Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8",
          "originalWidth": 2000,
          "originalHeight": 1334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/gCZCsUJlU_eGSKICIOeYWw--~B/aD0xMzM0O3c9MjAwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 2000,
              "height": 1334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/WHyHD1H6zLz3nNV.CBM0Ug--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/bloomberg_holding_pen_162/00f63695f3b0f194ef1f36849c9017e8.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Bloomberg",
          "url": "https://www.bloomberg.com/company"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-novo-lower-obesity-drug-170539017.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T21:05:00+00:00",
    "headline": "Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines.",
    "url": "https://finance.yahoo.com/news/lilly-announces-two-executive-committee-210500275.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "32875aaa-580c-3bf5-857c-f6534f42caa4",
      "content": {
        "id": "32875aaa-580c-3bf5-857c-f6534f42caa4",
        "contentType": "STORY",
        "title": "Lilly announces two new Executive Committee members and expansion of leadership roles to prepare for next wave of growth",
        "description": "",
        "summary": "Eli Lilly and Company (NYSE: LLY) today announced the appointment of two new Executive Committee members and the expansion of other senior leaders' roles designed to accelerate one of the industry's most ambitious pipelines, generate new portfolio opportunities, and strengthen patient access to its medicines.",
        "pubDate": "2025-11-06T21:05:00Z",
        "displayTime": "2025-11-06T21:05:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee",
          "originalWidth": 400,
          "originalHeight": 219,
          "caption": "Eli Lilly and Company logo. (PRNewsFoto, Eli Lilly and Company)",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/7Y1fhfHoGbpYMTG8q90VAg--~B/aD0yMTk7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 400,
              "height": 219,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.Goic7S8PJ1_UseTWpNhHw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/f3aaa8410f59c3eccd5d187ecffbd6ee.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/lilly-announces-two-executive-committee-210500275.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/lilly-announces-two-executive-committee-210500275.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "DNLI"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T21:00:00+00:00",
    "headline": "Denali Therapeutics Announces Board and Executive Leadership Updates",
    "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice Pr",
    "url": "https://finance.yahoo.com/news/denali-therapeutics-announces-board-executive-210000404.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "96dbbc0b-c9e9-3636-9d8f-633a57cee102",
      "content": {
        "id": "96dbbc0b-c9e9-3636-9d8f-633a57cee102",
        "contentType": "STORY",
        "title": "Denali Therapeutics Announces Board and Executive Leadership Updates",
        "description": "",
        "summary": "SOUTH SAN FRANCISCO, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (NASDAQ: DNLI) today announced updates to its Board of Directors and executive leadership team. Tim Van Hauwermeiren has been appointed to Denali’s Board of Directors. Mr. Van Hauwermeiren is co-founder and Chief Executive Officer of argenx. Carole Ho, M.D., who has served as Denali’s Chief Medical Officer and Head of Development since 2015, will be departing to join Eli Lilly and Company as Executive Vice Pr",
        "pubDate": "2025-11-06T21:00:00Z",
        "displayTime": "2025-11-06T21:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b",
          "originalWidth": 1302,
          "originalHeight": 334,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/yil_.q2z_cqg0CXVVyhAAQ--~B/aD0zMzQ7dz0xMzAyO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b.cf.webp",
              "width": 1302,
              "height": 334,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EJ8R0copyTs1BY7q_LPgnw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/9413467aa7ac7369471890c186d51b4b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/denali-therapeutics-announces-board-executive-210000404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/denali-therapeutics-announces-board-executive-210000404.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "DNLI"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:59:27+00:00",
    "headline": "Eli Lilly, Novo Nordisk to Cut Drug Prices, Get Tariff Relief Under Deals With Trump Administration",
    "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe",
    "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "39ff2f6a-b4ad-3e8d-94af-974184c8615a",
      "content": {
        "id": "39ff2f6a-b4ad-3e8d-94af-974184c8615a",
        "contentType": "STORY",
        "title": "Eli Lilly, Novo Nordisk to Cut Drug Prices, Get Tariff Relief Under Deals With Trump Administration",
        "description": "",
        "summary": "Eli Lilly (LLY) and Novo Nordisk (NVO) will reduce US prices for their popular weight-loss and diabe",
        "pubDate": "2025-11-06T20:59:27Z",
        "displayTime": "2025-11-06T20:59:27Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b",
          "originalWidth": 1000,
          "originalHeight": 667,
          "caption": "pillsdrugspharmacy - Shutterstock",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_47DdDax2mFqu9DGfd1IHg--~B/aD02Njc7dz0xMDAwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b.cf.webp",
              "width": 1000,
              "height": 667,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/.2HxBgHtuHXuuB3ZiLaY3w--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/mt_newswires_premium_news_706/a9e560796fb7d27244aee8d495d8603b.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/eli-lilly-novo-nordisk-cut-205927557.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T18:47:11+00:00",
    "headline": "Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic",
    "summary": "America's waistline may shrink, but its national debt will swell.",
    "url": "https://finance.yahoo.com/news/trump-punches-35-billion-hole-184711550.html",
    "source": "Fortune",
    "provider": "yfinance",
    "raw": {
      "id": "ae7ac1e3-2355-32bc-9b77-2a075306e9bf",
      "content": {
        "id": "ae7ac1e3-2355-32bc-9b77-2a075306e9bf",
        "contentType": "STORY",
        "title": "Trump punches new $35 billion hole in national debt with deal for Medicare to cover your Ozempic",
        "description": "",
        "summary": "America's waistline may shrink, but its national debt will swell.",
        "pubDate": "2025-11-06T18:47:11Z",
        "displayTime": "2025-11-06T18:47:11Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/fortune_175/7779772e8b3d85675bf2897db4a17591",
          "originalWidth": 2048,
          "originalHeight": 1365,
          "caption": "President Donald Trump.",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/EO78k1b07b3DEdqHlP9Mkw--~B/aD0xMzY1O3c9MjA0ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/fortune_175/7779772e8b3d85675bf2897db4a17591.cf.webp",
              "width": 2048,
              "height": 1365,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/MdQdpabrxb2fYAdO_31Mpw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/fortune_175/7779772e8b3d85675bf2897db4a17591.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Fortune",
          "url": "http://fortune.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/trump-punches-35-billion-hole-184711550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/trump-punches-35-billion-hole-184711550.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            },
            {
              "symbol": "NOVO-B.CO"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T22:30:00+00:00",
    "headline": "Trump inks Eli Lilly & Novo deals: How to play pharma stocks",
    "summary": "US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
    "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
    "source": "Yahoo Finance Video",
    "provider": "yfinance",
    "raw": {
      "id": "769e7adf-e9cc-3ea5-84c7-c65dbab0e6d4",
      "content": {
        "id": "769e7adf-e9cc-3ea5-84c7-c65dbab0e6d4",
        "contentType": "VIDEO",
        "title": "Trump inks Eli Lilly & Novo deals: How to play pharma stocks",
        "description": "<p>US President Trump announced deals with Novo Nordisk (<a data-i13n=\"cpos:1;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) and Eli Lilly (<a data-i13n=\"cpos:2;pos:1\" href=\"https://finance.yahoo.com/quote/LLY\">LLY</a>) to secure lower prices of the companies' GLP-1 drugs.</p>\n<p>Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host <a data-i13n=\"cpos:3;pos:1\" href=\"https://finance.yahoo.com/author/josh-lipton/\">Josh Lipton</a> to take a closer look at what the deals mean for the companies.</p>\n<p>Breen also discusses Pfizer's (<a data-i13n=\"cpos:4;pos:1\" href=\"https://finance.yahoo.com/quote/PFE\">PFE</a>) legal case to block Novo Nordisk's (<a data-i13n=\"cpos:5;pos:1\" href=\"https://finance.yahoo.com/quote/NVO\">NVO</a>) Metsera (<a data-i13n=\"cpos:6;pos:1\" href=\"https://finance.yahoo.com/quote/MTSR\">MTSR</a>) acquisition.</p>\n<p>To watch more expert insights and analysis on the latest market action, check out more <a data-i13n=\"cpos:7;pos:1\" href=\"https://finance.yahoo.com/videos/series/market-domination-overtime/\">Market Domination Overtime</a>.</p>",
        "summary": "US President Trump announced deals with Novo Nordisk (NVO) and Eli Lilly (LLY) to secure lower prices of the companies' GLP-1 drugs. Bernstein US biopharmaceuticals senior analyst Courtney Breen joins Market Domination Overtime host Josh Lipton to take a closer look at what the deals mean for the companies. Breen also discusses Pfizer's (PFE) legal case to block Novo Nordisk's (NVO) Metsera (MTSR) acquisition. To watch more expert insights and analysis on the latest market action, check out more Market Domination Overtime.",
        "pubDate": "2025-11-06T22:30:00Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809",
          "originalWidth": 7390,
          "originalHeight": 4161,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/SrpCArzSoYHL3BazC.HdrQ--~B/aD00MTYxO3c9NzM5MDthcHBpZD15dGFjaHlvbg--/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809.cf.webp",
              "width": 7390,
              "height": 4161,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/Bpg8katqiAezzsIF3339xw--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://s.yimg.com/os/creatr-uploaded-images/2025-11/fd7d82f0-bb59-11f0-9bee-5bf59c188809.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Yahoo Finance Video",
          "url": "https://finance.yahoo.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-inks-eli-lilly-novo-223000229.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": true
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "NONOF"
            },
            {
              "symbol": "NVO"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T21:37:25+00:00",
    "headline": "Trump drug pricing deal may squeeze Novo, Lilly margins, expert says",
    "summary": "<body><p>STORY: \"I think initially, [stocks] rallied on the idea that, 'Hey, we're going to have the opportunity to sell more of this product to more and more people, that should be good for us,\" Landsberg said, after the deal was announced.</p><p>But later in the day, he noted that investors may be having \"a second thought saying, 'But what if the U.S. government's in there [and they're] gonna really drive down some of our margins?\"</p></body>",
    "url": "https://finance.yahoo.com/video/trump-drug-pricing-deal-may-213725644.html",
    "source": "Reuters Videos",
    "provider": "yfinance",
    "raw": {
      "id": "908641b7-ed9e-3266-b92f-825c3c66c72c",
      "content": {
        "id": "908641b7-ed9e-3266-b92f-825c3c66c72c",
        "contentType": "VIDEO",
        "title": "Trump drug pricing deal may squeeze Novo, Lilly margins, expert says",
        "description": "<title><body><p>STORY: \"I think initially, [stocks] rallied on the idea that, 'Hey, we're going to have the opportunity to sell more of this product to more and more people, that should be good for us,\" Landsberg said, after the deal was announced.</p><p>But later in the day, he noted that investors may be having \"a second thought saying, 'But what if the U.S. government's in there [and they're] gonna really drive down some of our margins?\"</p></body></title>",
        "summary": "<body><p>STORY: \"I think initially, [stocks] rallied on the idea that, 'Hey, we're going to have the opportunity to sell more of this product to more and more people, that should be good for us,\" Landsberg said, after the deal was announced.</p><p>But later in the day, he noted that investors may be having \"a second thought saying, 'But what if the U.S. government's in there [and they're] gonna really drive down some of our margins?\"</p></body>",
        "pubDate": "2025-11-06T21:37:25Z",
        "displayTime": "",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://s.yimg.com/uu/api/res/1.2/3pJ4eYkvF47jINTwnzpkSw--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d5aec3cb-6dc6-46d3-934a-8b7be426af8d/main/1280x720/33s706ms/match/image.jpg",
          "originalWidth": 1280,
          "originalHeight": 720,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/LO.iFRSJ8X3vOqdg68Xf5Q--~B/aD03MjA7dz0xMjgwO2FwcGlkPXl0YWNoeW9u/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d5aec3cb-6dc6-46d3-934a-8b7be426af8d/main/1280x720/33s706ms/match/image.jpg.cf.webp",
              "width": 1280,
              "height": 720,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/RJYVVkz.0NmUOMRRRXIrmA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://cf-images.us-east-1.prod.boltdns.net/v1/jit/6415665815001/d5aec3cb-6dc6-46d3-934a-8b7be426af8d/main/1280x720/33s706ms/match/image.jpg.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Reuters Videos",
          "url": "http://www.reuters.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/video/trump-drug-pricing-deal-may-213725644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/video/trump-drug-pricing-deal-may-213725644.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "LLY"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-06T20:47:24+00:00",
    "headline": "RBC Capital Remains Bullish on Walmart (WMT), Cites Leadership Position, Pricing Discipline, and Long-Term Growth Potential",
    "summary": "Walmart Inc. (NYSE:WMT), which accounts for 1.86% of Bill Gates’s stock portfolio, is one of his top 15 stock picks. On October 29, 2025, RBC Capital’s Steven Shemesh raised his price target on Walmart Inc. (NYSE:WMT) from $106 to $116, reiterating his “Outperform” rating, The Fly reported. This price revision follows investor meetings with Walmart Inc.’s (NYSE:WMT) […]",
    "url": "https://finance.yahoo.com/news/rbc-capital-remains-bullish-walmart-204724064.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "0fd70643-b377-3001-a7ac-e2855810d281",
      "content": {
        "id": "0fd70643-b377-3001-a7ac-e2855810d281",
        "contentType": "STORY",
        "title": "RBC Capital Remains Bullish on Walmart (WMT), Cites Leadership Position, Pricing Discipline, and Long-Term Growth Potential",
        "description": "",
        "summary": "Walmart Inc. (NYSE:WMT), which accounts for 1.86% of Bill Gates’s stock portfolio, is one of his top 15 stock picks. On October 29, 2025, RBC Capital’s Steven Shemesh raised his price target on Walmart Inc. (NYSE:WMT) from $106 to $116, reiterating his “Outperform” rating, The Fly reported. This price revision follows investor meetings with Walmart Inc.’s (NYSE:WMT) […]",
        "pubDate": "2025-11-06T20:47:24Z",
        "displayTime": "2025-11-06T20:47:24Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/01bcee9d7ad5681a021049784ed4de6c",
          "originalWidth": 750,
          "originalHeight": 563,
          "caption": "RBC Capital Remains Bullish on Walmart (WMT), Cites Leadership Position, Pricing Discipline, and Long-Term Earnings Growth Potential",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/K8fJXSVmePmNJefkVIhgiA--~B/aD01NjM7dz03NTA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/01bcee9d7ad5681a021049784ed4de6c.cf.webp",
              "width": 750,
              "height": 563,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1LJmXS6ZF1G.ZEJrqgusiQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/01bcee9d7ad5681a021049784ed4de6c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-remains-bullish-walmart-204724064.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/rbc-capital-remains-bullish-walmart-204724064.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "WMT"
            },
            {
              "symbol": "LLY"
            },
            {
              "symbol": "OPAI.PVT"
            },
            {
              "symbol": "SNAP"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]